{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T11:14:56Z","timestamp":1684926896790},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Dr. Reddy's Laboratories, Hyderabad, India"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40119-022-00253-x","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T09:42:47Z","timestamp":1644399767000},"page":"129-141","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population"],"prefix":"10.1007","volume":"11","author":[{"given":"Jamshed","family":"Dalal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Sreenivas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdish","family":"Hiremath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Yunus","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Gaurav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amey","family":"Mane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sucheta","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavesh","family":"Meel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Subramaniyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"issue":"13","key":"253_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/atm.2016.06.33","volume":"4","author":"F Sanchis-Gomar","year":"2016","unstructured":"Sanchis-Gomar F. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256. https:\/\/doi.org\/10.21037\/atm.2016.06.33.","journal-title":"Ann Transl Med"},{"issue":"1","key":"253_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7860\/JCDR\/2014\/6359.3908","volume":"8","author":"S Shah","year":"2014","unstructured":"Shah S, et al. Comparative evaluation of efficacy, safety and haemostatic parameters of enoxaparin and fondaparinux in unstable coronary artery disease. J Clin Diagn Res. 2014;8(1):31\u20134. https:\/\/doi.org\/10.7860\/JCDR\/2014\/6359.3908.","journal-title":"J Clin Diagn Res"},{"issue":"12","key":"253_CR3","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1517\/17425250903456039","volume":"5","author":"V Chaturvedi","year":"2009","unstructured":"Chaturvedi V, Karthikeyan G. Fondaparinux in acute coronary syndromes. Expert Opin Drug Metab Toxicol. 2009;5(12):1615\u201323. https:\/\/doi.org\/10.1517\/17425250903456039.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"253_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.NAJ.0000351508.39509.e2","volume":"109","author":"KJ Overbaugh","year":"2009","unstructured":"Overbaugh KJ. Acute coronary syndrome. Am J Nurs. 2009;109(5):42\u201353. https:\/\/doi.org\/10.1097\/01.NAJ.0000351508.39509.e2.","journal-title":"Am J Nurs"},{"issue":"25","key":"253_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1161\/CIR.0000000000000134","volume":"23","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, et al.AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology American Heart Association task force on practice guidelines. Circulation. 2014;23(25):344\u2013426. https:\/\/doi.org\/10.1161\/CIR.0000000000000134.","journal-title":"Circulation"},{"issue":"6","key":"253_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1586\/14779072.5.6.1013","volume":"5","author":"JP Bassand","year":"2007","unstructured":"Bassand JP, et al. Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007;5(6):1013\u201326. https:\/\/doi.org\/10.1586\/14779072.5.6.1013.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"253_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/bmj.326.7401.1259","volume":"326","author":"D Grech Ever","year":"2003","unstructured":"Grech Ever D, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 2003;326:1259. https:\/\/doi.org\/10.1136\/bmj.326.7401.1259.","journal-title":"BMJ"},{"key":"253_CR8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/bmj.326.7401.1259","volume":"326","author":"ED Grech","year":"2003","unstructured":"Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 2003;326:1259. https:\/\/doi.org\/10.1136\/bmj.326.7401.1259.","journal-title":"BMJ"},{"issue":"4","key":"253_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0885066613503294","volume":"30","author":"N Makki","year":"2015","unstructured":"Makki N, et al. Acute coronary syndrome. J Intensive Care Med. 2015;30(4):186\u2013200. https:\/\/doi.org\/10.1177\/0885066613503294.","journal-title":"J Intensive Care Med"},{"issue":"2","key":"253_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ihj.2017.06.017","volume":"70","author":"AM Adam","year":"2018","unstructured":"Adam AM, et al. Prognostic value of blood count parameters in patients with acute coronary syndrome. Indian Heart J. 2018;70(2):233\u201340. https:\/\/doi.org\/10.1016\/j.ihj.2017.06.017.","journal-title":"Indian Heart J"},{"issue":"4","key":"253_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/vhrm.2006.2.4.371","volume":"2","author":"AG Turpie","year":"2006","unstructured":"Turpie AG. Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc Health Risk Manag. 2006;2(4):371\u20138. https:\/\/doi.org\/10.2147\/vhrm.2006.2.4.371.","journal-title":"Vasc Health Risk Manag"},{"issue":"9219","key":"253_CR12","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","volume":"355","author":"JW Eikelboom","year":"2000","unstructured":"Eikelboom JW, et al. Unfractionated heparin and low-molecular-weight heparin in ACS without ST elevation: a meta-analysis [published correction appears in Lancet 2000 Aug 12;356(9229):600]. Lancet. 2000;355(9219):1936\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(00)02324-2.","journal-title":"Lancet"},{"issue":"14","key":"253_CR13","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"EM Antman","year":"2006","unstructured":"Antman EM, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477\u201388. https:\/\/doi.org\/10.1056\/NEJMoa060898.","journal-title":"N Engl J Med"},{"issue":"3","key":"253_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1586\/14779072.7.3.241","volume":"7","author":"G Karthikeyan","year":"2009","unstructured":"Karthikeyan G, et al. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Rev Cardiovasc Ther. 2009;7(3):241\u20139. https:\/\/doi.org\/10.1586\/14779072.7.3.241.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"12","key":"253_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/2040620717733691","volume":"8","author":"JY Moon","year":"2017","unstructured":"Moon JY, et al. The role of oral anticoagulant therapy in patients with acute coronary syndrome. Ther Adv Hematol. 2017;8(12):353\u201366. https:\/\/doi.org\/10.1177\/2040620717733691.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"253_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.15420\/icr.2017:26:1","volume":"13","author":"EN Onwordi","year":"2018","unstructured":"Onwordi EN, et al. Anticoagulant therapy for acute coronary syndromes. Interv Cardiol. 2018;13(2):87\u201392. https:\/\/doi.org\/10.15420\/icr.2017:26:1.","journal-title":"Interv Cardiol"},{"issue":"6","key":"253_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2016.03.003","volume":"81","author":"DR Caterina","year":"2016","unstructured":"Caterina DR, Goto S. Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. Vascul Pharmacol. 2016;81(6):1\u201314. https:\/\/doi.org\/10.1016\/j.vph.2016.03.003.","journal-title":"Vascul Pharmacol"},{"issue":"11","key":"253_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12968\/bjca.2012.7.11.545","volume":"7","author":"N Hamedi","year":"2013","unstructured":"Hamedi N, Wright P. Fondaparinux and acute coronary syndrome. Br J. 2013;7(11):15\u201326. https:\/\/doi.org\/10.12968\/bjca.2012.7.11.545.","journal-title":"Br J"},{"issue":"3","key":"253_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5935\/abc.20160127","volume":"107","author":"ADM Soeiro","year":"2016","unstructured":"Soeiro ADM, et al. Fondaparinux versus enoxaparin\u2014which is the best anticoagulant for acute coronary syndrome? Brazilian Registry Data. Arq Bras Cardiol. 2016;107(3):239\u201344. https:\/\/doi.org\/10.5935\/abc.20160127.","journal-title":"Arq Bras Cardiol"},{"key":"253_CR20","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1002\/14651858.CD007038.pub2","volume":"1","author":"V Brito","year":"2011","unstructured":"Brito V, et al. Factor Xa inhibitors for acute coronary syndromes. Cochrane Database Syst Rev. 2011;1:7038. https:\/\/doi.org\/10.1002\/14651858.CD007038.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"253_CR21","first-page":"321","volume":"3","author":"H Wienbergen","year":"2007","unstructured":"Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag. 2007;3(3):321\u20139.","journal-title":"Vasc Health Risk Manag"},{"issue":"7","key":"253_CR22","first-page":"83","volume":"63","author":"A Trailokya","year":"2015","unstructured":"Trailokya A, et al. Fondaparinux in acute coronary syndromes. J Assoc Physicians India. 2015;63(7):83\u20137.","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"253_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ccd.26279","volume":"88","author":"C Larmore","year":"2016","unstructured":"Larmore C, et al. Real-world comparison of prasugrel with ticagrelor in patients with ACS treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv. 2016;88(4):535\u201344. https:\/\/doi.org\/10.1002\/ccd.26279.","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-022-00253-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T03:32:33Z","timestamp":1647660753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-022-00253-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1007\/s40119-022-00253-x","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}